IN THE SPECIFICATION

Please amend the specification as follows:

Please amend the paragraph starting on page 1, line 8 to read as follows:

This application claims ~~the benefit of~~ priority under 35 U.S.C. § 120 to U.S. Application No. 09/881,033, filed June 12, 2001, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/211,245, filed June 12, 2000, each ~~the content~~ of which is incorporated herein by reference in its entirety.

Please amend the paragraph starting on page 19, line 12 to read as follows:

~~Figure 12~~ Figures 12A and 12B. Reduced susceptibility and drug-dependent stimulation of viral replication in of a site-directed mutants with HIV RT mutations K103N, 135T, and V245T, as described in Example 13. The results from each mutant are compared to results obtained from a drug susceptible virus control, such as PNL4-3, or HXB-2. Although mutations at each HIV RT codon position alone did not result in drug-dependent stimulation, the triple mutant exhibits drug-dependent stimulation for all three NNRTIs (delavirdine, efavirenz, or nevirapine), In these graphs, stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition).

Please amend the paragraph starting on page 21, line 4 to read as follows:

~~Figure 18~~ Figures 18A and 18B. Patient 014451, reduced susceptibility to NNRTI ~~an~~ and drug dependent stimulation of viral replication associated with mutations at codon 101, codon 106 and codon 190 (Example 7).